NCT03457948 - Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 27, 2018

Primary Completion Date

July 31, 2025

Study Completion Date

May 31, 2026

Conditions

Metastatic Malignant Neoplasm in the LiverNeuroendocrine Neoplasm

Interventions

PROCEDURE

Arterial Embolization

Undergo TAE

BIOLOGICAL

Pembrolizumab

Given IV

BIOLOGICAL

Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate

Given IV

DEVICE

Yttrium-90 Microsphere Radioembolization

Undergo yttrium-90 microsphere RE

Trial Locations (1)

University of California, San Francisco, San Francisco